The endogenous mouse Cd274(also known as PD-L1) gene was replaced by human PD-L1 gene . While hPD-L1(2)(Stock No.NM-HU-190039) mice function similarly to hPD-L1 mice,for more detailed information please contact our technical advisor.
Fig1. Expression of PD-L1 in the spleen lymphocytes collected from homozygous humanized PD-L1 mice and wild-type mice is detected by FACS. The results showed that the expression of human PD-L1 can be detected in both T cells and B cells collected from the spleen of homozygous humanized PD-L1 mice. (Completed in collaboration with CrownBio)
Fig2. Immunotype in blood , spleen and bone marrow in hPD-L1 mice.
Fig3. Immunotype in blood in hPD-L1 mice.
Fig4. Immunotype in spleen in hPD-L1 mice.
Fig5. Immunotype in bone marrow in hPD-L1 mice.
Fig6. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized PD-L1 mice. Homozygous humanized PD-L1 mice were inoculated with MC38 colon cancer cells (expressing human PDL1 rather than murine PD-L1). After the tumors grew to 100 mm3, the animals were randomly assigned into a control group and a treatment group (n=5). The results showed: The antibodies targeting human PD-L1 were associated with a very significant anti-tumor effect (TGI: tumor growth inhibition, p < 0.001), demonstrating that the humanized PD-L1 mice are a good in vivo model for validating the efficacy of antibodies targeting human PD-L1.
You may also like
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.Learn more
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.Learn more